Groupe Bruxelles Lambert SA stock (BE0003797140): new Rayner co-control deal shapes portfolio valuation picture

Groupe Bruxelles Lambert SA shares on Euronext Brussels traded around EUR 80.65 on 05/29/2026 after the Belgian investment holding confirmed the completion of a EUR 500 million transaction to acquire a 45% co-controlling stake in UK-based intraocular lens manufacturer Rayner alongside CVC, according to Zonebourse on 05/29/2026 and Marketscreener on 05/29/2026.

The company said on 05/29/2026 that the deal, announced earlier with CVC, gives it joint control over Rayner, a specialist in ophthalmic surgical products, adding another healthcare-focused asset to its European portfolio, as reported by Marketscreener and Zonebourse on 05/29/2026.

The stock’s one-day move of about -0.31% on Euronext Brussels on 05/29/2026 came against the backdrop of a portfolio valued at EUR 12.8 billion at the end of 2025, with listed assets making up roughly 54.3% of the total, according to Marketscreener data updated on 05/29/2026.

As of: 05/29/2026

By the editorial team - specialized in equity coverage.

Groupe Bruxelles Lambert SA: core business model

Groupe Bruxelles Lambert SA operates as a diversified investment platform that allocates long-term capital into a concentrated portfolio of European listed and private companies, generating returns mainly through dividends, portfolio revaluations and occasional disposals.

Recent corporate actions

On 05/29/2026, Groupe Bruxelles Lambert said it had finalized the acquisition of a 45% co-controlling interest in UK-based Rayner via a EUR 500 million transaction carried out with CVC, expanding its presence in the ophthalmic medical device segment, according to Marketscreener and Zonebourse on 05/29/2026.

Valuation metrics and multiples for Groupe Bruxelles Lambert SA

According to the Euronext Paris-style quote information compiled by Zonebourse on 05/29/2026, Groupe Bruxelles Lambert’s share price performance showed a one-day change of -0.31%, a one-week move of -0.74% and a decline over the current month, while the stock was still trading above its 52-week low but below its 52-week high as of late May 2026.

Marketscreener data as of 05/29/2026 also indicate that GBL’s net asset value is underpinned by a portfolio worth about EUR 12.8 billion at the end of 2025, with more than half in listed holdings such as SGS, Pernod Ricard and adidas, which means the market price on Euronext Brussels can trade at a discount or premium to this underlying asset base depending on investor sentiment toward its sector mix, governance and capital allocation policy.

Conclusion

The closing of the EUR 500 million Rayner co-control deal alongside CVC gives Groupe Bruxelles Lambert SA additional exposure to the ophthalmic medtech space while reaffirming its role as a long-term European investment platform.

With the stock trading modestly lower on Euronext Brussels on 05/29/2026 and the underlying portfolio valued at EUR 12.8 billion at the end of 2025, investors are likely to watch how this new asset and the broader mix of listed and private holdings influence the company’s valuation metrics over the coming quarters.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.